Key facts
- It has raised $1.4M; the latest was Later Stage VC ($1.4M) in Nov 2025.
- Notable investors include CoInvest Capital, Innovation Agency Lithuania, Iron Wolf Capital, NGL Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Self.co
- ·The full record, as it builds
Funding rounds
No funding rounds for Self.co are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Self.co
Developer of diagnostic systems designed to facilitate the detection of allergies and food intolerances through in-vitro testing. The company offers a platform featuring a comprehensive range of tests, such as allergy panels for IgG, IgE, and IgG4, food intolerance assessments, and stool analysis, enabling individuals seeking to understand their sensitivities to access detailed diagnostic information and make informed dietary and health management decisions.
- Sector
- Healthcare
- HQ
- Vilnius, Lithuania
- Founded
- 2015
- Website
- self.co/
- Ownership
- Privately Held (backing)
Self.co doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Self.co shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Self.co in its N-PORT filings yet. We sweep new filings monthly.